Sleep公司联合科研机构推出新型睡眠暂停测技术

一种新型软件运算法则使用了一种人工智能以及神经网络，并同时使用脉搏血氧测定仪，来检测阻塞性睡眠暂停(OSA)和潮式呼吸（Cheyne-Stokes呼吸，CSR）。

这种技术是根据213项睡眠研究中血氧测定仪记录到的分析结果而开发的。已经证实这套软件在诊断OSA和CSR方面具有极高的敏感性和特异性。这项技术是由美国布法罗大学医学与生物医学科学院(UB, NY, USA)研制开发的。OSA仅仅在美国就影响了180万人，同时还有90％患者没有诊断出来。

布法罗大学已经与Sleep解决方案公司(Annapolis, MD, USA)签订了一项协议，将这种新型检测技术进行商品化并投放市场。Sleep公司为这项新技术提供在家庭内的诊断、治疗以及监护睡眠呼吸疾病（尤其式OSA）的服务。

根据布法罗大学研究部临时副总裁 兼布法罗大学科学办公室主任Robert J. Genco的说法，“在全球范围的临床实践中，对阻塞性睡眠暂停与潮式呼吸的诊断，迫切需要一种价廉物美的方法。我们十分自信Sleep公司将能够把这种崭新的技术投向市场，从而为大众的需要提供低成本的操作简便的诊断公斤。”
 
New Testing Technology for Sleep Apnea
 
A new software algorithm uses a form of artificial intelligence, a neural network, to detect (OSA) and Cheyne-Stokes respiration (CSR), along with a pulse oximetry signal.

The technology is based on the analysis of the oximetric recordings of 213 sleep studies. The software has demonstrated very high sensitivities and specificities for diagnosing OSA and CSR.

The technology was developed at the University of Buffalo School of Medicine and Biomedical Sciences (UB, NY, USA). OSA affects 18 million people in the United States alone, with as many as 90% going undiagnosed.

The University of Buffalo has signed an agreement with Sleep Solutions, Inc. (Annapolis, MD, USA) to commercialize and distribute the new testing technology. Sleep Solutions provides technology and testing services for at-home diagnosis, therapy, and care of sleep-disordered breathing, particularly OSA.

According to Robert J. Genco, UB interim vice president for research and director of the UB Office of Science, there is “a growing worldwide clinical need to provide a cost-effective solution for diagnosis of obstructive sleep apnea and Cheyne-Stokes respiration. We are very confident that Sleep Solutions will be able to bring this novel technology to the marketplace resulting in a lower-costing, easier-to-implement diagnostic tool for the public good.”